Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Study of the Safety and Efficacy of a True Human Antibody, 514G3, in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus

NCT02357966 is registered in ClinicalTrials.gov with XBiotech, Inc. as lead sponsor.

NCT NCT02357966
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02357966 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Study of the Safety and Efficacy of a True Human Antibody, 514G3, in Subjects Hospitalized With Bacteremia Due to Staphylococcus Aureus
Lead sponsor
XBiotech, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2015
Completion date
December 31, 2016
Enrollment
52 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

staphylococcus aureus bacteremia